XHKG
2219
Market cap210mUSD
Oct 09, Last price
2.38HKD
1D
0.00%
1Q
-5.56%
IPO
-85.61%
Name
Chaoju Eye Care Holdings Ltd
Chart & performance
P/E
7.67
P/S
1.03
EPS
0.26
Div yield, %
5.01%
Shrs. gr., 5y
0.27%
Rev. gr., 5y
11.36%
Revenues
1.36b
-3.21%
Net income
183m
-5.96%
CFO
339m
-4.22%
Dividend
May 14, 20260.2423 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, myopia prevention and control, dry eye syndrome, and oculoplastic, as well as optical products and services. The company also provides treatment for eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases, and pediatric eye diseases. In addition, it offers Amblyopia recovery services; and sells eyewear, equipment, and optical products. Chaoju Eye Care Holdings Limited was founded in 1988 and is headquartered in Beijing, China.
Key people
Weichao Wang
Chief Financial Officer · since 2021
Hongyan Liu
Chief Operating Officer · since 2020
Bozhou Zhang
Executive Chairman of the Board, Chief Executive Officer · since 2020
Xiaoli Zhang
Executive Director · since 2020
Junfeng Zhang
Executive Director · since 2020
Chun Xie
Chief Strategy Officer · since 2025
Yajun Yang
Chief Medical Officer · since 2020
Wai Kin Lo
Joint Company Secretary · since 2026
Guangdi Zhang
Executive Director, Joint Company Secretary · since 2026
Mao Chen
Non-Executive Director · since 2020
Non-Executive Director · since 2020
Li Zhang
Non-Executive Director · since 2023
Shan Bao
Non-Executive Independent Director · since 2021
Hongyan Guo
Non-Executive Independent Director · since 2021
Mingguang He
Non-Executive Independent Director · since 2021
Non-Executive Independent Director · since 2021
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||